The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therapy. This combination, targeting the GPRC5D protein on myeloma cells, showed significant improvements in progression-free survival (up to 81%) and overall survival (up to 89%) at 24 months in a Phase 3 study. If approved, it would be the only bispecific antibody combo targeting GPRC5D available from the second line of treatment, offering a new immunotherapy approach that preserves healthy immune cells. Johnson & Johnson aims to provide deeper, longer-lasting responses earlier in the treatment course for multiple myeloma patients.
Johnson & Johnson's stock is trading at USD 262.85 on Pluang, down 1.78% in the last day, reflecting some market caution despite the positive news. As of Oct 24, 2026 01:11 WIB, the company holds a market cap of $644.22 billion with a dividend yield of 2%.
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
Johnson & Johnson has increased its dividend annually for 64 years, yet its stock returns over the past decade were outpaced by the S&P 500 index. While a $1,000 investment in J&J grew to about $2,957 with dividends reinvested, the S&P 500 grew even ...
